Preclinical studies demonstrated the specific activity of a CLL-1-specific chimeric antigen receptor T cells (CLL-1 CAR-Ts) against CLL-1+ AML cell lines and primary AML patient samples in vitro. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.